Prostate cancer ibuprofen research
A study has shown that combining ibuprofen, an over-the-counter nonsteroidal anti-inflammatory drug (NSAID), and EGCG from green tea dramatically slows the growth of prostate cancer cells by 90%.
Many chemicals, behaviors, or events combine together with synergistic reactions. The results are multiplied, not just added--the whole is greater than the sum of its parts.
Ibuprofen and green tea
One new synergistic combination with a positive result may be ibuprofen and EGCG, the primary polyphenol antioxidant catechin in green tea.
The preliminary study using prostate cancer cells tested ibuprofen and EGCG separately and together.
Ibuprofen alone reduced prostate cancer cell growth by 25% and EGCG alone reduced prostate cancer cell growth by 20%.
90% reduction of prostate cancer cell growth
However, when ibuprofen and EGCG from green tea were used together, prostate cancer cell growth was reduced by 90%.
Using the combination dosage, the mechanisms identified included apoptosis or cell death, and oxidative stress involving ceramide synthesis (Kim MH, Synergistic cell death by EGCG and ibuprofen in DU-145 prostate cancer cell line, Anticancer Research, December 2007).
While this is a preliminary study, it opens doors for research on improving therapies by combining commonly used chemicals.
What is ibuprofen?
Ibuprofen is an over the counter (OTC) nonsteroidal anti-inflammatory drug (NSAID).
It is used for pain relief during colds, headaches, minor fevers, arthritic attacks, and other mild conditions.
EGCG has many benefits beyond its usefulness as the potent antioxidant found primarily in green tea.
Here are more studies showing green tea reduces the risk up to 90% of prostate cancer.
Can you really buy that doctor's guide to prostate cancer book for $0.01?
More health info with free subscription to the Green Tea Health Newsletter here:
This page last updated by Sharon Jones.
Was this page on prostate cancer ibuprofen helpful? Here's more health info
Subscribe now and don't miss a single issue.
Find out more!